Lexeo Therapeutics Partners with Investors to Launch $40M RNA Cardiac Therapeutics Spinout
Key Insights
Lexeo Therapeutics announced a strategic partnership with Perceptive Xontogeny Venture Funds (search) and venBio Partners (search) to create a new entity focused on RNA-based therapies for genetic cardiac diseases (search) using non-viral delivery platforms.
The partnership involves up to $40 million in funding that is non-dilutive to existing Lexeo shareholders, with Lexeo receiving a double-digit equity position and rights to future milestones and royalties.
The new biotech aims to address cardiac genetic diseases that existing AAV platforms cannot treat, targeting a genetic and precision cardiology market estimated to grow from $13 billion to nearly $40 billion by 2033.
Lexeo Therapeutics has announced a strategic partnership with leading life-sciences investors Perceptive Xontogeny Venture Funds (search) and venBio Partners (search) to launch a new biotechnology entity focused on RNA-based therapeutics for genetic cardiac diseases (search). The collaboration involves up to $40 million in private equity financing that will be non-dilutive to existing Lexeo shareholders.
Novel Approach to Cardiac Genetic Medicine
The new entity will advance research for RNA-based therapeutics using non-viral delivery methods to treat genetically mediated cardiac conditions. This approach represents a significant departure from current adeno-associated virus (AAV) platforms, potentially addressing cardiac genetic diseases that existing technologies cannot treat.
"Delivery of DNA by adeno-associated virus has defined the first wave of genetic medicine, with potential to treat cardiovascular diseases (search) that other modalities cannot address today," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "Over the next decade, however, new modalities will emerge allowing genetic medicines to treat an even broader range of cardiac diseases, and RNA therapeutics mediated by non-viral delivery are representative of this future."
Strategic Partnership Structure
Under the agreement terms, Lexeo will contribute its expertise in developing cardiac genetic medicines, certain existing preclinical intellectual property, and technology, which will be combined with a novel non-viral delivery platform. As consideration for its contributions, Lexeo has received a double-digit percentage equity position in the new entity and will be entitled to future milestone payments, royalties, and opt-in rights to certain programs.
The partnership reflects what Townsend described as "an innovative approach to realize the therapeutic and economic value of promising preclinical science in a manner that benefits all stakeholders."
Market Opportunity and Investment Rationale
The genetic and precision cardiology market presents substantial growth potential, with current valuations estimated at over $13 billion this year and projected to reach almost $40 billion by 2033.
"We see this as one of the most promising areas in biotech, where there is both a significant need and clear opportunity for innovation through the development of RNA therapeutics for cardiac disease," said Fred Callori, PXV Funds Managing Director. "This collaboration brings together the right expertise, science, and strategic areas of focus to pursue and advance these treatments."
Corey Goodman, venBio Managing Partner, emphasized the unmet medical need in this space: "Lexeo is a leader in cardiac genetic medicine and there is a significant unmet need for broadening precision approaches in this category. We look forward to working with Lexeo to launch this new entity and foster innovation that has the potential to fundamentally change the treatment paradigm for patients with devastating heart conditions."
Lexeo's Current Pipeline and Recent Developments
Lexeo Therapeutics is currently advancing a portfolio of therapeutic candidates targeting genetic causes of cardiovascular conditions, including LX2006 for Friedreich ataxia cardiomyopathy (search) and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy (search). Both programs are in early human studies.
Interim results from an early-stage trial showed LX2006 reduced signs associated with heart complications among study participants. The company has an agreement with the FDA on the design of a planned registrational study, which will assess the drug's efficacy by measuring frataxin (search) protein levels and reductions in left ventricular mass index.
The company has faced operational challenges, including a smaller-than-projected IPO in 2023 and a 15% workforce reduction earlier this year. Lexeo has also been seeking business development opportunities for its Alzheimer's disease (search) treatment portfolio.